Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome

Abstract Treatment of locally advanced, unresectable head and neck squamous cell carcinoma (HNSCC) often yields only modest results with radiochemotherapy (RCT) as standard of care. Prognostic features related to outcome upon RCT might be highly valuable to improve treatment. Monocarboxylate transpo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Martin Leu, J. Kitz, Y. Pilavakis, S. Hakroush, H. A. Wolff, M. Canis, S. Rieken, M. A. Schirmer
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/65dee9ff75eb467db2485a259080b37c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:65dee9ff75eb467db2485a259080b37c
record_format	dspace
spelling	oai:doaj.org-article:65dee9ff75eb467db2485a259080b37c2021-12-02T15:52:59ZMonocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome10.1038/s41598-021-84019-w2045-2322https://doaj.org/article/65dee9ff75eb467db2485a259080b37c2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84019-whttps://doaj.org/toc/2045-2322Abstract Treatment of locally advanced, unresectable head and neck squamous cell carcinoma (HNSCC) often yields only modest results with radiochemotherapy (RCT) as standard of care. Prognostic features related to outcome upon RCT might be highly valuable to improve treatment. Monocarboxylate transporters-1 and -4 (MCT1/MCT4) were evaluated as potential biomarkers. A cohort of HNSCC patients without signs for distant metastases was assessed eliciting 82 individuals eligible whereof 90% were diagnosed with locally advanced stage IV. Tumor specimens were stained for MCT1 and MCT4 in the cell membrane by immunohistochemistry. Obtained data were evaluated with respect to overall (OS) and progression-free survival (PFS). Protein expression of MCT1 and MCT4 in cell membrane was detected in 16% and 85% of the tumors, respectively. Expression of both transporters was not statistically different according to the human papilloma virus (HPV) status. Positive staining for MCT1 (n = 13, negative in n = 69) strongly worsened PFS with a hazard ratio (HR) of 3.1 (95%-confidence interval 1.6–5.7, p < 0.001). OS was likewise affected with a HR of 3.8 (2.0–7.3, p < 0.001). Multivariable Cox regression confirmed these findings. We propose MCT1 as a promising biomarker in HNSCC treated by primary RCT.Martin LeuJ. KitzY. PilavakisS. HakroushH. A. WolffM. CanisS. RiekenM. A. SchirmerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Martin Leu J. Kitz Y. Pilavakis S. Hakroush H. A. Wolff M. Canis S. Rieken M. A. Schirmer Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome
description	Abstract Treatment of locally advanced, unresectable head and neck squamous cell carcinoma (HNSCC) often yields only modest results with radiochemotherapy (RCT) as standard of care. Prognostic features related to outcome upon RCT might be highly valuable to improve treatment. Monocarboxylate transporters-1 and -4 (MCT1/MCT4) were evaluated as potential biomarkers. A cohort of HNSCC patients without signs for distant metastases was assessed eliciting 82 individuals eligible whereof 90% were diagnosed with locally advanced stage IV. Tumor specimens were stained for MCT1 and MCT4 in the cell membrane by immunohistochemistry. Obtained data were evaluated with respect to overall (OS) and progression-free survival (PFS). Protein expression of MCT1 and MCT4 in cell membrane was detected in 16% and 85% of the tumors, respectively. Expression of both transporters was not statistically different according to the human papilloma virus (HPV) status. Positive staining for MCT1 (n = 13, negative in n = 69) strongly worsened PFS with a hazard ratio (HR) of 3.1 (95%-confidence interval 1.6–5.7, p < 0.001). OS was likewise affected with a HR of 3.8 (2.0–7.3, p < 0.001). Multivariable Cox regression confirmed these findings. We propose MCT1 as a promising biomarker in HNSCC treated by primary RCT.
format	article
author	Martin Leu J. Kitz Y. Pilavakis S. Hakroush H. A. Wolff M. Canis S. Rieken M. A. Schirmer
author_facet	Martin Leu J. Kitz Y. Pilavakis S. Hakroush H. A. Wolff M. Canis S. Rieken M. A. Schirmer
author_sort	Martin Leu
title	Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome
title_short	Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome
title_full	Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome
title_fullStr	Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome
title_full_unstemmed	Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome
title_sort	monocarboxylate transporter-1 (mct1) protein expression in head and neck cancer affects clinical outcome
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/65dee9ff75eb467db2485a259080b37c
work_keys_str_mv	AT martinleu monocarboxylatetransporter1mct1proteinexpressioninheadandneckcanceraffectsclinicaloutcome AT jkitz monocarboxylatetransporter1mct1proteinexpressioninheadandneckcanceraffectsclinicaloutcome AT ypilavakis monocarboxylatetransporter1mct1proteinexpressioninheadandneckcanceraffectsclinicaloutcome AT shakroush monocarboxylatetransporter1mct1proteinexpressioninheadandneckcanceraffectsclinicaloutcome AT hawolff monocarboxylatetransporter1mct1proteinexpressioninheadandneckcanceraffectsclinicaloutcome AT mcanis monocarboxylatetransporter1mct1proteinexpressioninheadandneckcanceraffectsclinicaloutcome AT srieken monocarboxylatetransporter1mct1proteinexpressioninheadandneckcanceraffectsclinicaloutcome AT maschirmer monocarboxylatetransporter1mct1proteinexpressioninheadandneckcanceraffectsclinicaloutcome
_version_	1718385512554692608

Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome

Ejemplares similares